Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme

Daiichi SankyoDaiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017, a collaborative drug discovery initiative for universities and research institutes in Europe. TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it has expanded outside of Japan, opening up to researchers in Germany, Switzerland and Austria and became known as TaNeDS Global Programme. Since 2014, it has expanded further across Europe to include all EU member states and was renamed "TaNeDS Europe" in 2015. The aim of this programme is increasing collaborative opportunities with researchers in Europe.

About TaNeDS Europe 2017 Collaborative Drug Discovery Programme

1. Eligible Countries

All EU member states plus Iceland, Norway, Switzerland and Israel

2. Candidate Research for Application

New drug-target discovery, drug-target validation, and innovative technological research that could result in novel drug discovery and development

3. Research Themes

(1) Cancer

New mechanisms and drug-target validation study for small-molecule and biologic treatments (antibody drugs, etc.)

(2) Pain and Sensory Neuron Disorder

New mechanisms and drug treatments for pain and sensory neuronal systems in vision/hearing loss

(3) End-Organ Diseases

New targets and mechanisms of end-organ diseases from heart, kidney, liver and vascular diseases

(4) Other Internal Diseases

New mechanisms and drug treatments for rare diseases, gastrointestinal disorder and anaemia

(5) Cell Therapy

Research on novel somatic stem/progenitor cells, adoptive T-cell therapy and new technology on cell/gene modification

(6) Revolutionary Drug Discovery Technology

Novel technology on oncology, nucleic acid therapeutics, gene therapy and drug metabolism and pharmacokinetics

For more details, please visit TaNeDS Europe webpage at: http://www.daiichisankyo.com/rd/taneds/index.html

4. Budget and Period of Research

Depending on the project type, up to maximum of 80,000 (Type A) or 150,000 (Type B) euros (plus overhead) per year for collaborative research projects for 2 years

5. Eligibility

Researchers of any nationality employed by universities, research institutes and start-up companies within the EU as well as Iceland, Norway, Switzerland and Israel, who can conduct research in those countries

6. Selection criteria

By matching Daiichi Sankyo's research interests as well as demonstrating originality, potentiality and possibility of drug discovery

7. Schedule

Application period: January 10 to February 20, 2017

First shortlist selection period: Late February to Mid-March, 2017

Second shortlist selection period: April, 2017

On-site visit interview: Mid-May, 2017

Notification of final decisions: Early June, 2017

Start of research programmes: August 2017 and onward

About Selection Results for TaNeDS Europe 2015/2016 Collaborative Drug Discovery Programme

The selection for 2015/2016 resulted in four projects, and the three collaborations are currently underway having one under negotiation.

(1) Applications: 191

(2) Selected: 4

The themes of four selected proposals are Cancer Biologics (Switzerland), Sensory Neuron (the Netherlands), Rare Diseases (Ireland), and Anaemia (Sweden).

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...